Cellevate develops and markets products based on a proprietary nanofiber-based platform - the Cellevat3d™ - with the potential to revolutionize upstream bioprocessing from R&D to commercial manufacturing. Our latest product line in development – Cellevat3d™ carriers – with a commercial launch planned for 2024, provides extracellular-like environments with exceptional surface areas for adherent cell cultures. Initial results show tremendous potential to increase yields, minimize risk and reduce costs in development and manufacturing.

We offer a range of products based on our versatile and easily functionalized platform for several applications, including next generation cell- and gene therapies.

For more information, please visit www.cellevate.com


Biotechnology

Manufacturing

Nanotechnology

Pharmaceutical

Cellevate AB

Cellevate AB's headquarters in Lund, Sweden

Laura Chirica

Jennifer Valdes

Jean - Christophe Bourdon

Raul Izquierdo

Nils Uhlin

Linda Dexlin Mellby

Maximilian Ottosson

Alexander Dahlquist

Albin Jakobsson

Description

People (6)

Laura Chirica

Albin Jakobsson

Maximilian Ottosson

Linda Dexlin Mellby

Nils Uhlin

Britt-Louise Rambäck

Jobs